Sandoz sues FDA over delay in first biogeneric approval.
作者信息
Fox Jeffrey L
出版信息
Nat Biotechnol. 2005 Nov;23(11):1327-8. doi: 10.1038/nbt1105-1327.
PMID:16273046
Abstract
摘要
相似文献
1
Sandoz sues FDA over delay in first biogeneric approval.
Nat Biotechnol. 2005 Nov;23(11):1327-8. doi: 10.1038/nbt1105-1327.
2
Path to approval proves rocky for copycat biodrugs.
Nature. 2005 Nov 10;438(7065):154-5. doi: 10.1038/438154a.
3
Lessons from Eprex for biogeneric firms.
Nat Biotechnol. 2003 Sep;21(9):956-7. doi: 10.1038/nbt0903-956.
4
Lawsuits anticipated on generic biologicals front.
Nat Biotechnol. 2003 Jul;21(7):721-2. doi: 10.1038/nbt0703-721.
5
Counterpoint: why biogenerics are a strawman.
Nat Biotechnol. 2006 Mar;24(3):269. doi: 10.1038/nbt0306-269.
6
Point: why biogenerics make sense.
Nat Biotechnol. 2006 Mar;24(3):268-9. doi: 10.1038/nbt0306-268b.
7
Biotech industry struggles with generics approval.
Nature. 2004 Jun 10;429(6992):588. doi: 10.1038/429588b.
8
Bills target biosimilar drugs.
Nature. 2009 Mar 26;458(7237):394-5. doi: 10.1038/458394b.
9
A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
Suffolk Univ Law Rev. 2003;36(3):787-819.
10
How FDA approves biotechnology drugs.
Am Pharm. 1995 May;NS35(5):14-5.
Zotero 插件